Cellular Mechanism Identified for Severe Viral Hepatitis
By LabMedica International staff writers Posted on 29 Jan 2018 |
Image: T regulatory cells (also known as Tregs or Regulatory T cells) are essential cells that suppress immune responses of other cells, designed to limit excessive reactions and prevent autoimmunity. Tregs are characterized by the expression of CD4+, CD25+,and Foxp3+, while lacking CD127 (Photo courtesy of BioLegend).
It is known that activated immune cells of patients with viral hepatitis destroy hepatocyte, but its regulatory mechanism has not yet been described. Regulatory T cells (Tregs) inhibit activation of other immune cells and thus are important for homeostasis of the immune system.
However, recent studies contradictorily show that immune inhibitory functions of regulatory T cells weaken in inflammatory conditions and the cells secrete inflammatory cytokines in response. Meanwhile, such a phenomenon was not observed in viral hepatitis including types A, B and C.
Medical scientists at The Korea Advanced Institute of Science and Technology (Daejeon, Republic of Korea) analyzed blood samples collected from 63 patients with acute hepatitis A (AHA) at the time of hospitalization (and some at later time points) and 19 healthy donors in South Korea. Liver tissues were collected from patients with fulminant AHA during liver transplantation. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood and lymphocytes were isolated from liver tissues and analyzed by flow cytometry. Cytokine production from Treg cells (CD4+CD25+Foxp3+) was measured by immunofluorescence levels following stimulation with anti-CD3 and anti-CD28. Epigenetic stability of Treg cells was determined based on DNA methylation patterns.
The scientists found a higher proportion of CD4+CD25+Foxp3+ Treg cells from patients with AHA, compared with controls, and produced tumor necrosis factor (TNF) upon stimulation with anti-CD3 and anti-CD28 (11.2% versus 2.8%). DNA methylation analysis confirmed the identity of the Treg cells. TNF-producing Treg cells had features of T-helper 17 cells, including upregulation of RAR-related orphan receptor gamma (RORγt), which was required for TNF production. The Treg cells had reduced suppressive functions compared to Treg cells from controls. The frequency of TNF-producing Treg cells in AHA patients’ blood correlated with their serum level of alanine aminotransferase.
The authors concluded that Treg cells from patients with AHA have altered functions, compared with Treg cells from healthy individuals. Treg cells from patients with AHA produce higher levels of TNF, gain features of T-helper 17 cells, and have reduced suppressive activity. The presence of these cells is associated with severe liver injury in patients with AHA. Eui-Cheol Shin, MD, PhD, a professor and senior author of the study, said, “This is the first study on regulatory T cells that contributes to hepatocyte damage in viral hepatitis. It is significant for identifying the cells and the molecules that can be used as effective treatment targets for viral hepatitis in the future.” The study was originally published online on December 8, 2017, in the journal Gastroenterology.
Related Links:
The Korea Advanced Institute of Science and Technology
However, recent studies contradictorily show that immune inhibitory functions of regulatory T cells weaken in inflammatory conditions and the cells secrete inflammatory cytokines in response. Meanwhile, such a phenomenon was not observed in viral hepatitis including types A, B and C.
Medical scientists at The Korea Advanced Institute of Science and Technology (Daejeon, Republic of Korea) analyzed blood samples collected from 63 patients with acute hepatitis A (AHA) at the time of hospitalization (and some at later time points) and 19 healthy donors in South Korea. Liver tissues were collected from patients with fulminant AHA during liver transplantation. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood and lymphocytes were isolated from liver tissues and analyzed by flow cytometry. Cytokine production from Treg cells (CD4+CD25+Foxp3+) was measured by immunofluorescence levels following stimulation with anti-CD3 and anti-CD28. Epigenetic stability of Treg cells was determined based on DNA methylation patterns.
The scientists found a higher proportion of CD4+CD25+Foxp3+ Treg cells from patients with AHA, compared with controls, and produced tumor necrosis factor (TNF) upon stimulation with anti-CD3 and anti-CD28 (11.2% versus 2.8%). DNA methylation analysis confirmed the identity of the Treg cells. TNF-producing Treg cells had features of T-helper 17 cells, including upregulation of RAR-related orphan receptor gamma (RORγt), which was required for TNF production. The Treg cells had reduced suppressive functions compared to Treg cells from controls. The frequency of TNF-producing Treg cells in AHA patients’ blood correlated with their serum level of alanine aminotransferase.
The authors concluded that Treg cells from patients with AHA have altered functions, compared with Treg cells from healthy individuals. Treg cells from patients with AHA produce higher levels of TNF, gain features of T-helper 17 cells, and have reduced suppressive activity. The presence of these cells is associated with severe liver injury in patients with AHA. Eui-Cheol Shin, MD, PhD, a professor and senior author of the study, said, “This is the first study on regulatory T cells that contributes to hepatocyte damage in viral hepatitis. It is significant for identifying the cells and the molecules that can be used as effective treatment targets for viral hepatitis in the future.” The study was originally published online on December 8, 2017, in the journal Gastroenterology.
Related Links:
The Korea Advanced Institute of Science and Technology
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms